NZ599033A - A process for purifying staurosporine by seeding - Google Patents
A process for purifying staurosporine by seedingInfo
- Publication number
- NZ599033A NZ599033A NZ599033A NZ59903305A NZ599033A NZ 599033 A NZ599033 A NZ 599033A NZ 599033 A NZ599033 A NZ 599033A NZ 59903305 A NZ59903305 A NZ 59903305A NZ 599033 A NZ599033 A NZ 599033A
- Authority
- NZ
- New Zealand
- Prior art keywords
- staurosporine
- solution
- seeding
- solvent
- purifying
- Prior art date
Links
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 title abstract 5
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 title abstract 5
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000010899 nucleation Methods 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- 239000002904 solvent Substances 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 abstract 2
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 abstract 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 abstract 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical group O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Extraction Or Liquid Replacement (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62534304P | 2004-11-05 | 2004-11-05 | |
| US64213105P | 2005-01-07 | 2005-01-07 | |
| NZ588025A NZ588025A (en) | 2004-11-05 | 2005-11-03 | A process for purifying staurosporine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599033A true NZ599033A (en) | 2012-09-28 |
Family
ID=35501294
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599033A NZ599033A (en) | 2004-11-05 | 2005-11-03 | A process for purifying staurosporine by seeding |
| NZ588025A NZ588025A (en) | 2004-11-05 | 2005-11-03 | A process for purifying staurosporine |
| NZ554653A NZ554653A (en) | 2004-11-05 | 2005-11-03 | Organic compounds Comprising N-benzoyl-staurosporine |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ588025A NZ588025A (en) | 2004-11-05 | 2005-11-03 | A process for purifying staurosporine |
| NZ554653A NZ554653A (en) | 2004-11-05 | 2005-11-03 | Organic compounds Comprising N-benzoyl-staurosporine |
Country Status (31)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021347A2 (en) * | 2006-08-16 | 2008-02-21 | Novartis Ag | Method for making solid dispersions of highly crystalline therapeutic compounds |
| EP2327706A1 (en) * | 2009-11-30 | 2011-06-01 | Novartis AG | Polymorphous forms III and IV of N-benzoyl-staurosporine |
| KR20160008267A (ko) | 2014-07-14 | 2016-01-22 | 주식회사 윈스 | 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템 |
| US20200010481A1 (en) | 2017-03-06 | 2020-01-09 | Teva Pharmaceutical Works Ltd. | Solid state forms of midostaurin |
| WO2019215759A1 (en) * | 2018-05-09 | 2019-11-14 | Alaparthi Lakshmi Prasad | An improved process for preparation of midostaurin |
| IT201900004729A1 (it) | 2019-03-29 | 2020-09-29 | Procos Spa | Processo per la preparazione di midostaurina ad elevato grado di purezza |
| WO2020261293A1 (en) * | 2019-06-24 | 2020-12-30 | Dr. Reddy's Laboratories Limited | Process for preparation of midostaurin |
| IT201900014346A1 (it) | 2019-08-08 | 2021-02-08 | Procos Spa | Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo |
| IT202000004291A1 (it) | 2020-03-02 | 2021-09-02 | Indena Spa | Processo per la purificazione di alcaloidi indolo carbazolici |
| CN111393454A (zh) * | 2020-05-07 | 2020-07-10 | 奥锐特药业(天津)有限公司 | 米哚妥林的新晶型及其制备方法 |
| CN115124551B (zh) * | 2021-03-24 | 2024-04-30 | 奥锐特药业(天津)有限公司 | 一种高纯度米哚妥林的制备方法 |
| WO2023205504A1 (en) * | 2022-04-22 | 2023-10-26 | Rutgers, The State University Of New Jersey | Formulations and methods for treating epidermolysis bullosa simplex and related conditions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373501A (en) | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
| JPS60185719A (ja) | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | 抗腫瘍剤 |
| IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5073633A (en) | 1989-03-23 | 1991-12-17 | Bristol-Myers Company | BMY-41950 antitumor antibiotic |
| US5096330A (en) * | 1990-06-21 | 1992-03-17 | M-B-W Inc. | Pitch control mechanism for a surface finishing machine |
| JPH05247055A (ja) * | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
| JPH05247955A (ja) | 1992-03-06 | 1993-09-24 | Taisei Corp | 擁壁の施工方法 |
| EP0575955B1 (en) | 1992-06-22 | 1999-09-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
| WO1995032975A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents |
| RU2191175C2 (ru) * | 1995-12-11 | 2002-10-20 | Сефалон, Инкорпорейтед | Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с |
| US6878804B1 (en) * | 1999-08-30 | 2005-04-12 | University Of Zurich | Synthesis of template-fixed β-hairpin loop mimetics |
| WO2002076432A2 (en) | 2001-03-26 | 2002-10-03 | Novartis Ag | Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer |
| KR100407758B1 (ko) * | 2001-08-27 | 2003-12-01 | 씨제이 주식회사 | 스타틴의 제조에 있어서 락톤화 방법 |
| US7608420B2 (en) * | 2003-04-22 | 2009-10-27 | Lonza Ag | Process for the recovery of staurosporine from a fermentation broth |
-
2005
- 2005-10-26 JO JO2005162A patent/JO2897B1/en active
- 2005-10-28 MY MYPI20055091A patent/MY147404A/en unknown
- 2005-10-28 GT GT200500311A patent/GT200500311A/es unknown
- 2005-10-28 MY MYPI20091911A patent/MY154878A/en unknown
- 2005-11-03 SI SI200531555T patent/SI1812448T1/sl unknown
- 2005-11-03 PL PL05803350T patent/PL1812448T3/pl unknown
- 2005-11-03 ES ES05803350T patent/ES2388142T3/es not_active Expired - Lifetime
- 2005-11-03 CN CN2012101018747A patent/CN102627658A/zh active Pending
- 2005-11-03 WO PCT/EP2005/011789 patent/WO2006048296A1/en not_active Ceased
- 2005-11-03 PT PT05803350T patent/PT1812448E/pt unknown
- 2005-11-03 BR BRPI0517689-1A patent/BRPI0517689A/pt not_active IP Right Cessation
- 2005-11-03 HR HRP20120652TT patent/HRP20120652T1/hr unknown
- 2005-11-03 NZ NZ599033A patent/NZ599033A/xx not_active IP Right Cessation
- 2005-11-03 JP JP2007539535A patent/JP5057986B2/ja not_active Expired - Lifetime
- 2005-11-03 CA CA2584911A patent/CA2584911C/en not_active Expired - Lifetime
- 2005-11-03 EP EP15171908.5A patent/EP2955186A1/en not_active Withdrawn
- 2005-11-03 RU RU2007120695/04A patent/RU2394038C2/ru active
- 2005-11-03 DK DK05803350.7T patent/DK1812448T3/da active
- 2005-11-03 AU AU2005300693A patent/AU2005300693B2/en not_active Expired
- 2005-11-03 EP EP10173464.8A patent/EP2272850B1/en not_active Expired - Lifetime
- 2005-11-03 EP EP05803350A patent/EP1812448B1/en not_active Expired - Lifetime
- 2005-11-03 US US11/718,029 patent/US8198435B2/en active Active
- 2005-11-03 KR KR1020127022582A patent/KR101265850B1/ko not_active Expired - Lifetime
- 2005-11-03 NZ NZ588025A patent/NZ588025A/en not_active IP Right Cessation
- 2005-11-03 KR KR1020127022584A patent/KR101289998B1/ko not_active Expired - Lifetime
- 2005-11-03 MX MX2011007303A patent/MX346525B/es unknown
- 2005-11-03 KR KR1020077010191A patent/KR101333851B1/ko not_active Expired - Lifetime
- 2005-11-03 MX MX2007005429A patent/MX2007005429A/es active IP Right Grant
- 2005-11-03 NZ NZ554653A patent/NZ554653A/en not_active IP Right Cessation
- 2005-11-03 CN CN2012104320940A patent/CN102993213A/zh active Pending
- 2005-11-04 PE PE2009000199A patent/PE20090433A1/es not_active Application Discontinuation
- 2005-11-04 AR ARP050104637A patent/AR052322A1/es not_active Application Discontinuation
- 2005-11-04 TW TW103130302A patent/TWI530501B/zh not_active IP Right Cessation
- 2005-11-04 PE PE2012002519A patent/PE20130377A1/es not_active Application Discontinuation
- 2005-11-04 TW TW094138677A patent/TWI433852B/zh not_active IP Right Cessation
- 2005-11-04 TW TW101122880A patent/TWI530500B/zh not_active IP Right Cessation
- 2005-11-04 TW TW101122882A patent/TWI455941B/zh not_active IP Right Cessation
- 2005-11-04 PE PE2005001297A patent/PE20060947A1/es not_active Application Discontinuation
-
2007
- 2007-04-19 IL IL182691A patent/IL182691A/en active IP Right Grant
- 2007-05-02 NO NO20072290A patent/NO338960B1/no unknown
- 2007-05-04 TN TNP2007000165A patent/TNSN07165A1/fr unknown
- 2007-05-22 MA MA29924A patent/MA29033B1/fr unknown
- 2007-12-19 HK HK15112508.3A patent/HK1211587A1/en unknown
-
2009
- 2009-10-13 RU RU2009137788/04A patent/RU2467012C2/ru active
- 2009-12-07 AU AU2009245817A patent/AU2009245817B2/en not_active Expired
-
2010
- 2010-08-19 IL IL207702A patent/IL207702A/en active IP Right Grant
-
2012
- 2012-01-16 IL IL217571A patent/IL217571A/en active IP Right Grant
- 2012-03-12 EC ECSP12007431 patent/ECSP12007431A/es unknown
- 2012-05-11 JP JP2012109447A patent/JP5701246B2/ja not_active Expired - Lifetime
- 2012-05-15 US US13/472,130 patent/US8710216B2/en not_active Expired - Lifetime
- 2012-08-21 CY CY20121100747T patent/CY1113059T1/el unknown
-
2015
- 2015-01-09 JP JP2015003634A patent/JP2015063569A/ja not_active Withdrawn
-
2016
- 2016-07-12 NO NO20161152A patent/NO340404B1/no unknown
-
2017
- 2017-01-13 JP JP2017004320A patent/JP2017061578A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009102155A3 (en) | Process for preparation of 2-methyl-2´-phenylpropionic acid derivatives and novel intermediate compounds | |
| RU2009137788A (ru) | Органические соединения | |
| TN2012000257A1 (en) | Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance | |
| JP2007532496A5 (cg-RX-API-DMAC10.html) | ||
| WO2008010238A3 (en) | Antidiabetic azabicyclo [3. 1. 0] hexan compounds | |
| IL198902A0 (en) | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | |
| WO2008096372A3 (en) | Process for preparing highly pure ezetimibe using novel intermediates | |
| US10040771B2 (en) | Method for preparing prostacyclin receptor agonist 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]-1-butanol | |
| WO2011064156A3 (de) | Verfahren zur herstellung von methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamat und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff | |
| ATE394379T1 (de) | 4-alkoxy-cyclohexan-1-amino-carbonsäureester und verfahren zu ihrer herstellung | |
| CN105198785B (zh) | 一种顺丁烯二酰亚胺类化合物及其制备与应用 | |
| WO2009124906A3 (en) | A polymorph of argatroban monohydrate and a process for its synthesis | |
| Xue et al. | Synthesis and structure–activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors | |
| JP2011511053A5 (cg-RX-API-DMAC10.html) | ||
| DE60107832D1 (en) | Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe | |
| CN101412664A (zh) | 2，4-二氯苯酚和2，5-二氯苯酚混合物的分离方法 | |
| WO2008093205A3 (en) | A method for the purification of rosuvastatin intermediate | |
| CN101824038B (zh) | 喜树碱及其类似物的制备方法 | |
| CN107365301B (zh) | 一种克唑替尼的合成方法及其中间体制备方法 | |
| Haldar et al. | Sodium borohydride–iodine mediated reduction of γ-lactam carboxylic acids followed by DDQ mediated oxidative aromatisation: a facile entry to N-aryl-formylpyrroles | |
| CN105315284A (zh) | 阿拉格列汀中间体的制备方法 | |
| CA2589146A1 (en) | Process for producing muscarine receptor antagonist and intermediate therefor | |
| CN104292293B (zh) | 一种度他雄胺杂质i的制备方法 | |
| JP2011522042A (ja) | タダラフィルの製造方法 | |
| DE60108112D1 (de) | Verfahren zur herstellung von carbostyril-derivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 NOV 2012 BY CPA GLOBAL Effective date: 20130117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 NOV 2015 BY CPA GLOBAL Effective date: 20130410 |
|
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH Effective date: 20140409 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2016 BY CPA GLOBAL Effective date: 20151002 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2017 BY CPA GLOBAL Effective date: 20161021 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 NOV 2018 BY CPA GLOBAL Effective date: 20171019 |
|
| LAPS | Patent lapsed |